Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest metastatic breast cancer Stories

2014-04-09 08:29:49

SAN FRANCISCO, April 9, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technologies, today announced that preclinical data for NKTR-102 and NKTR-214 were presented at the 2014 Annual Meeting of the American Association of Cancer Research (AACR) being held in San Diego, California. NKTR-102 Presentation Positive preclinical data was presented for NKTR-102...

2014-04-07 12:33:35

The Most Promising Emerging Agents in Development for Triple Negative Breast Cancer Target Only Specific Patient Subsets, According to Findings from Decision Resources Group BURLINGTON, Mass., April 7, 2014 /PRNewswire/ -- Decision Resources Group finds that due to the heterogeneity of triple negative breast cancer the most promising emerging agents in development, target only specific subsets of patients. The two novel emerging therapies niraparib (Tesaro) and Xtandi (Medivation/Astellas)...

2014-04-06 12:20:19

INDIANAPOLIS, April 6, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present early-stage data from several targeted cancer therapies - including bemaciclib "beh meh sye' klib" (LY2835219), its oral, cell-cycle inhibitor of CDK4/6 - that make up its diverse clinical oncology pipeline during the American Association for Cancer Research (AACR) Annual Meeting 2014 held in San Diego, Calif. from April 5 - 9. "Harnessing Breakthroughs - Targeting Cures" is the theme of this year's...

2014-04-04 12:27:03

SAN DIEGO, April 4, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that it will present data on the comparison of Cynviloq(TM) and Abraxane(®) (nab-paclitaxel) pharmacokinetics (PK) from animal studies. The PK data will be presented by Dr. Kouros Motamed, Vice President of Clinical Development & Nanomedicine on April 9 from 8:00 AM to...

2014-04-03 12:26:50

NEW YORK, April 3, 2014 /PRNewswire/ -- The Web Marketing Association has announced the winners of its 12(th)annual Internet Advertising Competition Awards. Digital communications company Greater Than One, Inc. (GTO) took home three of the top trophies for 2014: Best Pharmaceuticals Online Video, Best Energy Website, and Best Advocacy Online Video. http://photos.prnewswire.com/prnvar/20140403/NY97751LOGO Best Pharmaceuticals Online Video went to the Breast Cancer Awareness video GTO...

2014-04-01 00:21:53

SAN DIEGO, March 31, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that the first patient has been dosed in the pivotal clinical trial designed to support approval of Cynviloq for the treatment of metastatic breast cancer and non-small cell lung cancer. The registration trial referred to as TRIBECA(TM) (TRIal designed to evaluate BioEquivalence...

Peaches Could Inhibit Breast Cancer Spread
2014-03-26 12:41:00

Lee Rannals for redOrbit.com - Your Universe Online According to a study published in the Journal of Nutritional Biochemistry, peach extract could slow down the growth and spread of breast cancer. Scientists working with mice discovered that a mixture of phenolic compounds found in peach extract inhibits breast cancer metastasis. The team said that the compounds could be a new addition to therapies to help reduce the risk of metastasis, which is the primary killer in breast and many...

2014-03-24 12:30:19

Largest Study of Its Kind Shows Minimally Invasive Treatment May Slow Disease Progression in Liver While Maintaining Quality of Life SAN DIEGO, March 24, 2014 /PRNewswire-USNewswire/ -- A minimally invasive treatment that delivers cancer-killing radiation directly to tumors shows promise in treating breast cancer that has spread to the liver when no other treatment options remain, according to research being presented at the Society of Interventional Radiology's 39th Annual...

2014-03-18 08:32:43

-- ABRAXANE plus gemcitabine approved by the TGA for the first-line treatment of metastatic pancreatic cancer MELBOURNE, Australia, March 18, 2014 /PRNewswire/ -- Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce that ABRAXANE(®) (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in now approved by the Therapeutic Goods Administration (TGA) for the first-line treatment of metastatic pancreatic cancer. The TGA approved...

Scientists Identify Potent Driver Of Metastasis
2014-03-10 12:44:42

The Wistar Institute Protein Correlates with Breast, Bladder, Melanoma, and Thyroid Tumors An international team of researchers led by scientists at The Wistar Institute have discovered and defined LIMD2, a protein that can drive metastasis, the process where tumors spread throughout the body. Their study, published in the March issue of the journal Cancer Research, defines the structure of LIMD2 and correlates the protein in metastatic bladder, melanoma, breast, and thyroid tumors....